How to Source Tafenoquine Succinate for Pharmaceutical Formulation

Tafenoquine Succinate (Tablets, 150 mg) is classified under Antiemetic. It is therapeutically aligned with reference brands such as Krintafel (USA). This guide highlights key sourcing factors buyers should consider when procuring high-quality Tafenoquine Succinate for formulation, R&D, or bulk manufacturing.

Product Overview: Tafenoquine is a long-acting antimalarial medication used for both the prevention and treatment of m...

1. Regulatory Compliance & Documentation

Ensure suppliers provide:

• ✔ Valid DMF (Drug Master File)
• ✔ COA (Certificate of Analysis) for each batch
• ✔ GMP, ISO, or ICH Q7 compliance certificates

2. Purity, Grade & Specification Matching

Tafenoquine Succinate must meet exact grade and purity for your dosage form:

• ✔ USP / EP / JP grade verification
• ✔ Particle size distribution check
• ✔ Residual solvent and heavy metal limits

3. Supplier Reliability & Audit History

• ✔ Positive past audit reports
• ✔ Pharma client references
• ✔ Years of proven API manufacturing experience

4. Commercial Terms: Pricing, MOQ & Flexibility

• ✔ Transparent pricing
• ✔ Pilot batch MOQ flexibility
• ✔ Volume-based discounts

5. Lead Time, Inventory & Logistics

Typical lead time for Tafenoquine Succinate is 4–6 weeks.

• ✔ Emergency dispatch options
• ✔ Regional warehousing
• ✔ Special storage if needed

6. Formulation Support

• ✔ Technical datasheets
• ✔ Sample availability
• ✔ Stability study support

Conclusion

Sourcing Tafenoquine Succinate is more than procurement—it’s a strategic partnership. With its tablets form and 150 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.

Frequently Asked Questions For Sourcing of Tafenoquine Succinate